Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Neeson

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Blood|March 12, 2016
Allogeneic CAR19 cells clear ALLPaul Neeson
Immunological Investigations|August 19, 2006
Effects of the tumor microenvironment on the efficacy of tumor immunotherapyPaul Neeson, Yvonne Paterson
Oncoimmunology|June 28, 2012
Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?Andy Hsu, David S Ritchie, Paul Neeson
Cancer Immunology, Immunotherapy : CII|September 19, 2007
Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphomaPaul Neeson, Zhen Kun Pan, Yvonne Paterson
Immunotherapy|July 20, 2010
Drug-mediated and cellular immunotherapy in multiple myelomaDavid S Ritchie, Hang Quach, Kate Fielding, et al.
Current Topics in Microbiology and Immunology|June 1, 2010
Biology and clinical observations of regulatory T cells in cancer immunologyMichele W L Teng, David S Ritchie, Paul Neeson, et al.
Current Opinion in Immunology|February 19, 2014
Manipulating immune cells for adoptive immunotherapy of cancerPhillip K Darcy, Paul Neeson, Carmen S M Yong, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2005
Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumorsMary E Dominiecki, Gregory L Beatty, Zhen-Kun Pan, et al.
International Journal of Molecular Sciences|May 17, 2020
P53: A Guardian of Immunity Becomes Its Saboteur through MutationArjelle Decasa Agupitan, Paul Neeson, Scott Williams, et al.
Expert Opinion on Investigational Drugs|July 13, 2018
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphomaCarrie Van Der Weyden, Martine Bagot, Paul Neeson, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Blood|March 12, 2016
Allogeneic CAR19 cells clear ALLPaul Neeson
Immunological Investigations|August 19, 2006
Effects of the tumor microenvironment on the efficacy of tumor immunotherapyPaul Neeson, Yvonne Paterson
Oncoimmunology|June 28, 2012
Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?Andy Hsu, David S Ritchie, Paul Neeson
Cancer Immunology, Immunotherapy : CII|September 19, 2007
Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphomaPaul Neeson, Zhen Kun Pan, Yvonne Paterson
Immunotherapy|July 20, 2010
Drug-mediated and cellular immunotherapy in multiple myelomaDavid S Ritchie, Hang Quach, Kate Fielding, et al.
Current Topics in Microbiology and Immunology|June 1, 2010
Biology and clinical observations of regulatory T cells in cancer immunologyMichele W L Teng, David S Ritchie, Paul Neeson, et al.
Current Opinion in Immunology|February 19, 2014
Manipulating immune cells for adoptive immunotherapy of cancerPhillip K Darcy, Paul Neeson, Carmen S M Yong, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2005
Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumorsMary E Dominiecki, Gregory L Beatty, Zhen-Kun Pan, et al.
International Journal of Molecular Sciences|May 17, 2020
P53: A Guardian of Immunity Becomes Its Saboteur through MutationArjelle Decasa Agupitan, Paul Neeson, Scott Williams, et al.
Expert Opinion on Investigational Drugs|July 13, 2018
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphomaCarrie Van Der Weyden, Martine Bagot, Paul Neeson, et al.
Pageof 4